Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription

Articles published in
Cancer Chemother Pharmacol
    May 2022
  1. MASSAI L, Messori L, Carpentieri A, Amoresano A, et al
    The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study.
    Cancer Chemother Pharmacol. 2022 May 11. pii: 10.1007/s00280-022-04438.
    >> Share

    April 2022
  2. MANZO J, Puhalla S, Pahuja S, Ding F, et al
    A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2022 Apr 18. pii: 10.1007/s00280-022-04430.
    >> Share

  3. XU J, Gao Y, Luan X, Li K, et al
    An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
    Cancer Chemother Pharmacol. 2022 Apr 13. pii: 10.1007/s00280-022-04403.
    >> Share

  4. GREEN ML, Ma SC, Goble S, Giordano H, et al
    Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
    Cancer Chemother Pharmacol. 2022 Apr 10. pii: 10.1007/s00280-022-04413.
    >> Share

    October 2021
  5. ROY P, Biswas S, Acharyya S, Dasgupta C, et al
    Effect of carboplatin dose capping on survival in recurrent breast, ovary and head and neck cancers: a single institutional retrospective study.
    Cancer Chemother Pharmacol. 2021;88:731-740.
    >> Share

    July 2021
  6. SUGISAWA N, Higuchi T, Han Q, Hozumi C, et al
    Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Cancer Chemother Pharmacol. 2021;88:61-67.
    >> Share

    June 2021
  7. SOKOLENKO AP, Gorodnova TV, Bizin IV, Kuligina ES, et al
    Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
    Cancer Chemother Pharmacol. 2021 Jun 2. pii: 10.1007/s00280-021-04301.
    >> Share

    April 2021
  8. VAULEON E, Behal H, Lebellec L, Desbarbieux R, et al
    Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study.
    Cancer Chemother Pharmacol. 2021;87:533-541.
    >> Share

    January 2021
  9. LIU YK, Jia YJ, Liu SH, Ma J, et al
    FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-kappaB pathway.
    Cancer Chemother Pharmacol. 2021 Jan 3. pii: 10.1007/s00280-020-04215.
    >> Share

    October 2020
  10. HANSEN MKG, Smerdel MP, Waldstrom M, Andersen RF, et al
    Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients.
    Cancer Chemother Pharmacol. 2020 Oct 16. pii: 10.1007/s00280-020-04162.
    >> Share

    August 2020
  11. JIANG J, Wang S, Wang Z, Cai J, et al
    HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
    Cancer Chemother Pharmacol. 2020 Aug 2. pii: 10.1007/s00280-020-04120.
    >> Share

    June 2020
  12. ZHU Y, Liu Z, Qu Y, Zeng J, et al
    YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects.
    Cancer Chemother Pharmacol. 2020 Jun 9. pii: 10.1007/s00280-020-04098.
    >> Share

    April 2020
  13. SOYAMA H, Miyamoto M, Matsuura H, Iwahashi H, et al
    Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
    Cancer Chemother Pharmacol. 2020 Apr 11. pii: 10.1007/s00280-020-04070.
    >> Share

    January 2020
  14. WANG Z, Gao J, Ohno Y, Liu H, et al
    Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.
    Cancer Chemother Pharmacol. 2020 Jan 6. pii: 10.1007/s00280-019-04025.
    >> Share

    November 2019
  15. KASHANI B, Zandi Z, Bashash D, Zaghal A, et al
    Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid).
    Cancer Chemother Pharmacol. 2019 Nov 30. pii: 10.1007/s00280-019-03988.
    >> Share

  16. KUBECEK O, Martinkova J, Chladek J, Blaha M, et al
    Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer.
    Cancer Chemother Pharmacol. 2019 Nov 14. pii: 10.1007/s00280-019-03976.
    >> Share

    October 2019
  17. ZHENG Y, Zhu J, Zhang H, Liu Y, et al
    Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial.
    Cancer Chemother Pharmacol. 2019 Oct 18. pii: 10.1007/s00280-019-03963.
    >> Share

    April 2019
  18. MOORE K, Chan JK, Secord AA, Patel MR, et al
    Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Cancer Chemother Pharmacol. 2019;83:717-726.
    >> Share

    January 2019
  19. STARLING BR, Kumar P, Lucas AT, Barrow D, et al
    Mononuclear phagocyte system function and nanoparticle pharmacology in obese and normal weight ovarian and endometrial cancer patients.
    Cancer Chemother Pharmacol. 2019;83:61-70.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016